Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMUR2 | Q9GZQ4 | 5/20 | 0.61 |
| ▸ | NMUR1 | Q9HB89 | 5/20 | 0.61 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.57 |
| ▸ | NTSR1 | P30989 | 3/20 | 0.57 |
| ▸ | RAMP3 | O60896 | 1/20 | 0.56 |
| ▸ | CALCR | P30988 | 1/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.55 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30416476 | 0.90 | OPRD1 (0.69) | NMUR2NMUR1OPRD1OPRM1OPRK1 | |
| SCHEMBL29934595 | 0.89 | NMUR2 (0.58) | NMUR2NMUR1OPRD1NTSR1RAMP3 | |
| SCHEMBL31433178 | 0.89 | RAMP3 (0.52) | NMUR2NMUR1RAMP3CALCROPRM1 | |
| SCHEMBL30436277 | 0.88 | NTSR1 (0.60) | NMUR2NMUR1NTSR1OPRM1OPRK1 | |
| SCHEMBL31433412 | 0.88 | APLNR (0.58) | NMUR2NMUR1OPRD1OPRM1OPRK1 | |
| SCHEMBL30842156 | 0.88 | NMUR2 (0.65) | NMUR2NMUR1OPRD1OPRM1CXCR4 | |
| SCHEMBL30834921 | 0.88 | NMUR2 (0.65) | NMUR2NMUR1OPRD1OPRM1OPRK1 | |
| SCHEMBL30186436 | 0.87 | CXCR4 (0.58) | NMUR2NMUR1RAMP3CALCRCXCR4 | |
| SCHEMBL11191224 | 0.86 | OPRD1 (0.75) | NMUR2NMUR1OPRD1NTSR1OPRM1 | |
| Analog Of Dynorphin A SCHEMBL27861937 | 0.86 | OPRD1 (0.75) | NMUR2NMUR1OPRD1NTSR1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | CALICO LIFE SCIENCES LLC (US) | 2025-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | MICA, CD74, HLA-DRB1 | NMUR2 3261/4885NMUR1 3086/4885OPRD1 3640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.